Phase 2 ADHD Trial, Recruiting NCT07084649 Sponsor: Shanghai Mental Health Center Condition: ADHD
Back to Adhd

Phase 2 ADHD Trial, Recruiting

NCT07084649
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with ADHD according to the DSM-5 (the standard medical guide used to diagnose mental health conditions)
  • People whose ADHD symptoms have not improved enough after completing a full course of medication treatment, based on specific rating scale scores (confirm with trial site)
  • People aged 10 to 18 years old, of any gender
  • People with an IQ score above 70, as measured by a standard intelligence test used in China, meaning those with an intellectual disability would not be included
  • People whose inattention or hyperactivity/impulsivity symptoms are rated at a certain level of severity on a standard parent-completed questionnaire (confirm with trial site for exact score thresholds)
  • People who have never taken ADHD medication, are currently not taking any, or who have been on a stable medication routine for at least 4 weeks before the study starts and plan to continue that routine throughout — provided they are not taking stimulant medications
  • People who are right-handed

Who may not be able to join:

  • People for whom the brain stimulation treatment used in this trial (TMS) would be unsafe, including those with epilepsy, a cardiac pacemaker, a cochlear implant, or metal implants in the body
  • People for whom MRI scanning would be unsafe or not possible, including those with metal implants, claustrophobia, or certain tattoos
  • People with a history of epilepsy, brain disorders, traumatic brain injury, or serious physical health conditions
  • People with a history of violent behaviour or suicidal behaviour
  • People who also have another neurodevelopmental condition, such as autism spectrum disorder or tic disorders
  • People who have another primary psychiatric diagnosis, other than conduct disorder, oppositional defiant disorder, mild anxiety, or mild depression
  • People with a history of substance abuse
  • People who are currently receiving other non-medication treatments for ADHD, such as cognitive behavioural therapy or neurofeedback
  • Female participants who are pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +862134773243

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Shanghai Mental Health Center
Registry
ClinicalTrials.gov
Start date
1 January 2025
Est. completion
1 September 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Effectiveness as measured by SNAP-IV Parent Rating Scale (assessing inattention/hyperactivity-impulsivity); Clinical Global Impression-Severity Scale (CGI)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov